New York, October 29, 2024 - PRISM MarketView - NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has scheduled a Type C meeting with the U.S. Food and Drug Administration (FDA) on November 6, 2024, to discuss the design of its upcoming Phase 3 clinical trial for PrimeC, a potential treatment for Amyotrophic Lateral Sclerosis (ALS). The meeting will focus on finalizing the Phase 3 study design and assessing readiness for a future New Drug Application (NDA) submission. NeuroSense plans to provide an update on the meeting results after receiving the official minutes, expected approximately one month later.
PrimeC has shown promising results in earlier clinical trials, including a reduction in disease progression. Concurrently, NeuroSense is preparing to submit a regulatory dossier to Health Canada in Q2 2025, with a potential commercialization decision anticipated by Q1 2026. The company estimates the potential market opportunity for PrimeC in Canada alone to be approximately $100 million to $150 million in annual revenue.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities